Key facts
- It has raised $2.2M; the latest was Later Stage VC ($110K) in Mar 2025.
- Notable investors include European Commission, LIFTT, Bioengineering Laboratories, Como Venture, TERMIS ().
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Dialybrid
- ·The full record, as it builds
Funding rounds
No funding rounds for Dialybrid are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Dialybrid
Developer of novel arteriovenous vascular grafts designed to assist doctors in performing hemodialysis on patients. The company's grafts are three-layered semi-resorbable vascular prosthesis, which gradually integrates into the body of hemodialytic patients, owing to the hybrid nature of the material with which it is made, enabling doctors to remodel silk fibroin with the elasticity and stability of polyurethanes in the body, which improves the quality of life for patients.
- Sector
- Healthcare
- HQ
- Cantu, Italy
- Founded
- 2018
- Employees
- 7
- Website
- dialybrid.com/
- Ownership
- Privately Held (backing)
Dialybrid doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Dialybrid shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Dialybrid in its N-PORT filings yet. We sweep new filings monthly.